An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-Experienced HIV-1 Infected Patients

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

CDC Category C AIDS defining infections, Viral encephalitis, Rhabdomyolysis, Liver failure, Liver related deaths

Outcome Time Frame:

Followed till 6 months after drug discontinuation up to a total of 5 years.

Safety Issue:

Yes

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A4001067

NCT ID:

NCT00665561

Start Date:

March 2008

Completion Date:

October 2018

Related Keywords:

• Human Immunodeficiency Virus
• Maraviroc
• HIV-1
• Safety
• Non-interventional
• Acquired Immunodeficiency Syndrome
• HIV Infections
• Immunologic Deficiency Syndromes